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Dynamic changes in Mcl-1 expression 
regulate macrophage viability or commitment 
to apoptosis during bacterial clearance
Helen M. Marriott,1 Colin D. Bingle,1 Robert C. Read,1 Karen E. Braley,2 Guido Kroemer,3  
Paul G. Hellewell,4 Ruth W. Craig,2 Moira K.B. Whyte,1 and David H. Dockrell1
1Division of Genomic Medicine, University of Sheffield, Sheffield, United Kingdom. 2Department of Pharmacology and Toxicology,  
Dartmouth Medical School, Hanover, New Hampshire, USA. 3Centre National de la Recherché Scientifique, UMR 8125,  
Institut Gustave Roussy, Villejuif, France. 4Division of Clinical Sciences North, University of Sheffield, Sheffield, United Kingdom.
Macrophages are critical effectors of bacterial clearance and must retain viability, despite exposure to toxic bac-
terial products, until key antimicrobial functions are performed. Subsequently, host-mediated macrophage 
apoptosis aids resolution of infection. The ability of macrophages to make this transition from resistance to 
susceptibility to apoptosis is important for effective host innate immune responses. We investigated the role of 
Mcl-1, an essential regulator of macrophage lifespan, in this switch from viability to apoptosis, using the model 
of pneumococcal-associated macrophage apoptosis. Upon exposure to pneumococci, macrophages initially 
upregulate Mcl-1 protein and maintain viability for up to 14 hours. Subsequently, macrophages reduce expres-
sion of full-length Mcl-1 and upregulate a 34-kDa isoform of Mcl-1 corresponding to a novel BH3-only splice 
variant, Mcl-1Exon-1. Change in expression of Mcl-1 protein is associated with mitochondrial membrane permea-
bilization, which is characterized by loss of mitochondrial inner transmembrane potential and translocation of 
cytochrome c and apoptosis-inducing factor. Following pneumococcal infection, macrophages expressing full-
length human Mcl-1 as a transgene exhibit a delay in apoptosis and in bacterial killing. Mcl-1 transgenic mice 
clear pneumococci from the lung less efficiently than nontransgenic mice. Dynamic changes in Mcl-1 expression 
determine macrophage viability as well as antibacterial host defense.
Introduction
Macrophages are the resident professional phagocytes in nonin-
flamed tissues and survive in situ for extended periods of time (1). 
In keeping with this phenotype, macrophages exhibit inherent 
resistance to apoptosis and maintain viability in the presence of 
proapoptotic factors (2). Bacterial infection is a potent stimulus 
for apoptosis, and microbial virulence factors inhibit macrophage 
viability to impede antibacterial defenses (3). Surprisingly, macro-
phage apoptosis can also facilitate immune responses by limit-
ing bacterial replication (4). This apparent paradox suggests that 
optimal macrophage antibacterial responses require transient 
maintenance of cell viability in the face of proapoptotic stimuli, 
followed by apoptosis induction for maximal bacterial clearance 
and minimal immune-mediated tissue injury. The control of this 
switch in macrophage phenotype is therefore an essential regula-
tor of innate host defense.
The molecular basis of macrophage resistance to apoptosis 
includes expression of antiapoptotic Bcl-2 family members, among 
which Mcl-1 predominates in differentiated human macrophages 
(2). Mcl-1 was first identified as a molecule that is upregulated 
during differentiation of immature myeloid cells along the mono-
cyte/macrophage pathway (5). It is unique among antiapoptotic 
members of the Bcl-2 family in that it is an early-response gene that 
can be rapidly induced and turned over (6, 7). Mcl-1 is expressed 
during critical transitions in cell phenotype and protects against 
apoptosis during the initial steps of differentiation, exposure to 
growth stimuli, or the rapid response to potentially cytotoxic 
stimuli including chemotherapeutic agents, UV irradiation, and 
calcium ionophores (5, 8, 9). The importance of Mcl-1 to macro-
phage survival has been confirmed in Mcl-1 transgenic mice and 
by antisense inhibition in human macrophages (2, 10).
Antiapoptotic Bcl-2 family members exert their effect in part 
by maintaining mitochondrial homeostasis and inhibiting 
mitochondrial membrane permeabilization (MMP) (11). Mcl-1 is 
found in mitochondrial-enriched cell fractions and can heterodi-
merize with proapoptotic Bcl-2 family members, such as Bax and 
Bak, to prevent MMP (8, 12). Loss of Mcl-1 is an apical event in 
the apoptotic cascade, as illustrated by its downregulation during 
UV-induced or adenoviral protein E1A–induced apoptosis (12, 13). 
Mcl-1 is subject to differential splicing, resulting in the genera-
tion of proapoptotic splice variants (14, 15). Mcl-1 is, therefore, an 
ideal regulator of cell viability during rapidly evolving conditions 
of cell stress and could allow the dynamic changes in cell viability 
required during bacterial infection.
The most extensively studied model of host-mediated macro-
phage apoptosis involves the chronic intracellular pathogen 
Mycobacterium tuberculosis, in which apoptosis limits bacterial 
replication and, conversely, intracellular replication is prolonged 
by inhibiting apoptosis (4, 16). Mcl-1 expression is upregulated 
in macrophages by M. tuberculosis and inhibits host-mediated 
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apoptosis, hence promoting mycobacterial survival and chronic 
intracellular persistence (16). We have characterized a different 
model of host-mediated macrophage apoptosis involving Strepto-
coccus pneumoniae (the pneumococcus). This model does not exhibit 
chronic intracellular persistence of bacteria (17, 18). Instead, bacte-
ria are effectively eliminated through a response that proceeds in 2 
phases: an initial period of macrophage viability and intracellular 
bacterial killing, followed after 14–16 hours by apoptosis induc-
tion and clearance of bacteria. Inhibition of the latter phase of 
apoptosis induction reduces bacterial clearance in vitro and in vivo 
(17, 18). This model therefore allows analysis of both phases of the 
macrophage response to bacterial infection.
We used a model of pneumococcal-associated host-mediated 
macrophage apoptosis to test the hypothesis that Mcl-1 is critical 
to both initial maintenance of cell viability and subsequent induc-
tion of apoptosis. Mcl-1 was upregulated in association with the 
retention of cell viability after initial bacterial phagocytosis. Mcl-1 
was subsequently downregulated, and a protein of approximately 
34 kDa with an electrophoretic mobility corresponding to a novel 
proapoptotic BH3-only splice variant Mcl-1Exon-1 was upregulated, 
during the initiation of MMP and induction of apoptosis. These 
changes in Mcl-1 expression have a role in the response to infec-
tion, as macrophages from transgenic mice overexpressing Mcl-1 
demonstrated delayed MMP and impaired bacterial clearance in 
vitro. Mcl-1 transgenic mice demonstrated less effective clearance 
of bacteria from the lung in vivo. These findings demonstrate the 
importance of an Mcl-1–regulated switch from macrophage viabil-
ity to apoptosis for optimal host defense.
Results
A biphasic response in monocyte-derived macrophage expression of Mcl-1 pro-
tein is observed after phagocytosis of pneumococci. We have previously dem-
onstrated that after phagocytosis of pneumococci, an initial period 
of macrophage viability is followed by apoptosis (17). To investigate 
whether changes in Mcl-1 transcription occurred in macrophages 
in response to exposure to pneumococci, we performed RNase pro-
tection assays. Mcl-1 mRNA was upregulated upon pneumococcal 
infection (Figure 1A). To correlate Mcl-1 protein expression with 
macrophage survival and death, we serially measured Mcl-1 expres-
sion in monocyte-derived macrophages (MDMs) from 7 donors 6–20 
hours after infection. To take account of the interdonor variability 
inherent to MDMs, both a representative Western blot and a summa-
ry graph depicting protein expression for all 7 donors are presented, 
and protein expression is compared with the number of apoptotic 
cells at each time point (Figure 1, B–D). Mcl-1 levels were upregulated 
in infected MDMs compared with mock-infected MDMs for as long 
as 14 hours after infection. After this time point, all donors demon-
strated a progressive decline until Mcl-1 levels dropped below those 
observed in mock-infected MDMs. The time at which this occurred 
varied among donors, and the time at which Mcl-1 started to decline 
best predicted the onset of apoptosis in infected cultures (Figure 1D). 
To examine whether the alterations in Mcl-1 expression were part of 
a general alteration in antiapoptotic Bcl-2 proteins, we also examined 
Bcl-xL but found it to be unaltered (see data in Figure 4A).
Decreased Mcl-1 protein expression is associated with MMP dur-
ing pneumococcal-associated MDM apoptosis. MMP, inhibited by 
antiapoptotic Bcl-2 family members, occurs upstream of caspase 
Figure 1
Mcl-1 protein levels demonstrate biphasic variation in association with pneumococcal infection of macrophages. (A) Total RNA was extracted 
from MDMs 20 hours after mock infection (Spn–) or infection with pneumococci (Spn+), and Mcl-1 mRNA was detected by RNase protection 
assay. The results presented are typical of 5 donors tested, but the duration of mRNA elevation varied among donors. L32 and GAPDH served 
as loading controls. (B) Western blot of total protein from MDMs at the indicated time points after infection, probed with anti–Mcl-1 and anti-
actin antibodies. Data are representative of 7 independent experiments. (C) Mcl-1 band density from a series of MDMs as in B, quantified by 
densitometry (n = 7). P < 0.05, Mcl-1 at 6 hours vs. 12 hours; P < 0.001, 6 hours vs. 20 hours; Student’s t test. (D) Levels of nuclear apoptosis 
in the same series of MDMs as in C. P < 0.001, apoptosis at 6 hours vs. 16 hours, Student’s t test.
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activation in many pathways of programmed cell death (11). MMP is 
characterized by loss of mitochondrial inner transmembrane poten-
tial (Δψm) and the mitochondrial release of intermembrane proteins 
such as cytochrome c and apoptosis-inducing factor (AIF) (11, 19). 
Cytochrome c translocation was observed in infected MDMs 14–16 
hours after infection, and actin degradation was a feature of the late 
stages of apoptosis but occurred after translocation of cytochrome 
c and downregulation of Mcl-1 (Figure 2A). To exclude the possi-
bility that mitochondrial features of apoptosis are a consequence 
of a caspase amplification loop and occur downstream of caspase 
activation (11), we determined the relationship of mitochondrial 
permeability transition to caspase activation. Treatment with a pan-
caspase inhibitor, N-benzyloxycarbonyl–Val-Ala-Asp (O-methyl) 
fluoromethyl ketone (zVADfmk), did not suppress cytochrome c 
translocation (Figure 2B), suggesting that it occurs independently 
of caspase activation. Loss of Δψm is also a feature of pneumococcal-
associated macrophage apoptosis and is detected prior to nuclear 
fragmentation (Figure 2C). Loss of Δψm showed the same kinetics 
as cytochrome c translocation (Figure 2D) and was not prevented 
by caspase inhibition (data not shown). AIF has been implicated 
in pneumococcal-associated neuronal cell death (20). Nuclear frac-
tions from pneumococcal-infected (but not mock-infected) MDMs 
contained AIF and exhibited histone H1 degradation (Figure 2E). 
The earliest features of MMP were coincident with the initial decline 
in peak Mcl-1 protein expression, emphasizing that downregulation 
of Mcl-1 was an early event in apoptosis induction.
Production of a novel BH3-only isoform of Mcl-1 is a feature of 
pneumococcal-associated macrophage apoptosis. Analysis of Mcl-1 protein 
expression in MDMs after pneumococcal infection revealed induc-
tion of an additional band of approximately 34 kDa on Western 
blots probed with anti–Mcl-1 antibody (Figure 3A). In the series 
of MDMs derived from 7 different donors, expression of the band 
of approximately 34 kDa occurred from 12 hours after infection 
and prior to onset of MMP. Treatment of infected MDM cultures 
with the transcription inhibitor actinomycin D blocked expres-
sion of this protein (data not shown). We and others have shown 
that altered splicing of the Mcl-1 gene can result in production of 
a BH3-only proapoptotic protein (14, 15). The band of approxi-
mately 34 kDa detected in SDS-PAGE from infected MDMs exhib-
ited a higher electrophoretic mobility than the in vitro translation 
product of the Mcl-1S/ΔTM splice variant, but a migration similar 
to that of the product of the Mcl-1Exon-1 splice variant (Figure 3B). 
Mcl-1Exon-1 is the product of an mRNA that retains intron 1 and 
contains 230 amino acids that are shared with full-length Mcl-1 
and Mcl-1S/ΔTM plus an additional 4 amino acids (Figure 3C) (C.D. 
Bingle, unpublished observations). Upregulation of this isoform in 
Figure 2
Mitochondrial features of apoptosis are observed in macrophages infected with pneumococci. (A) Western blot of the cytosolic and mitochondrial 
(Mit) fractions from MDMs at the indicated time points after infection with pneumococci or mock infection probed with anti–cytochrome c and 
anti-actin antibodies. Results are derived from 2 donors and are representative of 2 independent experiments. (B) Western blot of the cytosolic 
fractions from MDMs 20 hours after infection in the presence (+) or absence (–) of zVADfmk or N-benzyloxycarbonyl–Phe-Ala fluoromethyl 
ketone (zFA) probed with anti–cytochrome c and anti-actin antibodies. Results are derived from 2 donors and are representative of 2 indepen-
dent experiments. (C) MDMs were stained with JC-1 and Hoechst 33342 (Ho33342) 20 hours after infection. Loss of Δψm is represented as a loss 
of punctate red staining, and nuclear morphology is detected by Hoechst 33342 staining. Data are representative of 3 donors. (D) Histograms 
representing Δψm of MDMs at the indicated time points after infection, stained with JC-1. The percentage of cells with preservation of Δψm (indi-
cated by the M1 marker) is shown. Results are representative of 3 independent experiments. (E) Western blot of nuclear fractions from MDMs 
20 hours after infection, probed with anti-AIF and Histone H1 antibodies. Data are representative of 3 independent experiments.
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response to infection was confirmed in the human monocytic cell 
line U937, where transfection with a construct encoding Mcl-1Exon-1 
or infection with pneumococci resulted in expression of an identical 
34-kDa protein that was distinct from Mcl-1S/ΔTM (Figure 3B). The 
proapoptotic function of Mcl-1Exon-1 was demonstrated in mock-
infected and pneumococcal-infected U937 cells, where transfection 
with a construct encoding Mcl-1Exon-1 both decreased cell viability 
and increased apoptosis (Figure 3, D and E). Levels of apoptosis in 
cells transfected with Mcl-1Exon-1 were comparable to those in cells 
transfected with the proapoptotic Bcl-2 family member Bax. Fur-
thermore, Mcl-1 transfection significantly decreased the percentage 
of apoptotic cells among the population positive for enhanced GFP 
(EGFP) after pneumococcal infection, as compared with transfection 
with empty vector. These results demonstrate the interplay between 
full-length Mcl-1 and Mcl-1Exon-1.
Mcl-1 contains caspase cleavage sites, and 4 caspase cleavage prod-
ucts of 17–28 kDa in size have been described (21). However, treat-
ment with zVADfmk failed to alter the abundance of Mcl-1Exon-1 
(Figure 4A). Similarly, caspase inhibition did not prevent the 
decrease in Mcl-1 expression associated with pneumococcal 
infection (data not shown). To exclude the possibility that other 
proteases active in infected MDMs might generate the isoform of 
Mcl-1 that was approximately 34 kDa, we treated cultures with 
inhibitors of cysteine or serine proteases, but none resulted in 
decreased expression of the protein (data not shown). Subcellular 
fractionation demonstrated that Mcl-1Exon-1, like Mcl-1, was local-
ized to the mitochondrial membrane, despite loss of the carboxyl 
hydrophobic tail associated with mitochondrial localization of 
the full-length protein (6) (Figure 4B). A small amount of Mcl-1 
was also apparent in the cytosolic fraction of mock-infected cells, but 
this became undetectable by the time cytochrome c first translocated 
to the cytoplasm. Mcl-1 downregulation can be a feature of cell stress 
pathways in which p53 accumulates (12). To determine whether 
Mcl-1Exon-1 expression is also induced by stimuli that induce apoptosis 
by downregulating full-length Mcl-1, we examined the effect of UV 
treatment on MDMs (13). As expected, UV irradiation induced 
nuclear fragmentation in MDMs (Figure 4C) and p53 upregulation 
(Figure 4D). Although UV irradiation was associated with Mcl-1 
downregulation, there was no evidence of production of Mcl-1Exon-1 
at any time point following UV exposure, suggesting that production 
of Mcl-1Exon-1 is not a feature of UV-mediated MDM apoptosis.
Proteasome-mediated degradation of Mcl-1 occurs in pneumococcal-
associated macrophage apoptosis. Mcl-1 is degraded by the ubiquitin-
proteasome pathway (13). Mcl-1 levels were increased in cell 
lysates following treatment with the proteasome inhibitor car-
bobenzoxy-L-leucyl-L-leucyl-L-leucinal (MG-132), regardless of 
whether they were mock-infected or infected (Figure 5A). At 
20 hours after infection, proteasome inhibition with MG-132 
increased levels of Mcl-1, although not to the same level as 
observed in mock-infected cultures, suggesting that proteasomal 
degradation by this pathway is not the sole explanation for 
loss of Mcl-1 protein. However, the increased levels of Mcl-1 
after proteasome inhibition were associated with decreased 
cytochrome c translocation to the cytosol in pneumococcal-
infected MDMs (Figure 5B). Furthermore, proteasome inhibi-
tion in pneumococcal-infected MDMs decreased nuclear features 
of apoptosis (Figure 5C). Although proteasome inhibition can 
reduce degradation of multiple antiapoptotic proteins in addi-
Figure 3
Pneumococcal infection of macrophages results in increased expression of a proapoptotic Mcl-1 isoform. (A) Western blot of total protein from 
MDMs at the indicated time points after infection with pneumococci, probed with anti–Mcl-1 and anti-actin antibodies showing the appearance 
of the band of approximately 34 kDa. The donor is representative of 1 of the series in Figure 1C. The mean levels of nuclear apoptosis at each 
time point for this donor are indicated. (B) Western blot of total protein from U937 cells or MDMs (3 donors in 3 separate experiments) 20 hours 
after infection with pneumococci or mock infection and U937 cells transfected with Mcl-1Exon-1 or empty vector probed with anti–Mcl-1 antibody, 
with in vitro translation of Mcl-1, Mcl-1S/ΔTM, and Mcl-1Exon-1 as standards. (C) Genomic organization of Mcl-1 and Mcl-1Exon-1. The filled regions 
represent the coding region of the 2 transcripts. (D) Percentage of nonviable infected or mock-infected U937 cells 16 hours after nucleofection 
with vectors containing full-length Mcl-1, Mcl-1Exon-1, Bax, or empty vector. Results represent the analysis of 3 separate experiments. P < 0.05, 
Spn– Mcl-1 vs. Spn– Mcl-1Exon-1; P < 0.05, Spn+ Mcl-1 vs. Spn+ Mcl-1Exon-1; Student’s paired t test. (E) Percentage of EGFP-positive cells dem-
onstrating features of apoptosis after DAPI staining in the same experiments as in D. P < 0.05, Spn– Mcl-1 vs. Spn– Mcl-1Exon-1; P < 0.05, Spn+ 
Mcl-1 vs. Spn+ Mcl-1Exon-1; P < 0.05, Spn+ empty vector vs. Spn+ Mcl-1; Student’s paired t test.
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tion to Mcl-1 (13), these results suggest that proteasome-medi-
ated degradation of Mcl-1 contributes to the loss of macrophage 
viability following phagocytosis of pneumococci.
Bone marrow–derived macrophages from Mcl-1 transgenic mice demon-
strate decreased apoptosis after pneumococcal infection. To further test the 
concepts that Mcl-1 contributes to the switch in macrophage pheno-
type and that abrogating this switch might negatively affect clearance 
of bacteria, we performed experiments with bone marrow–derived 
macrophages (BMDMs) derived from Mcl-1 transgenic mice or their 
nontransgenic littermates (10). Lysates from transgenic mice, but not 
those from nontransgenic mice, reacted with an anti–human Mcl-1 
antibody that does not detect murine Mcl-1 (Figure 6A). Transgenic 
BMDMs exposed to pneumococci also demonstrated preservation 
of Δψm (Figure 6, B and C), decreased translocation of cytochrome c 
from the mitochondria (data not shown), and fewer nuclear changes 
indicative of apoptosis than did nontransgenic BMDMs (Figure 6, 
D and E). Pneumococcal infection of BMDMs resulted in a decrease 
in expression of the Mcl-1 transgene (Figure 6F). Mcl-1Exon-1 protein 
was also found in the lysates of BMDMs from Mcl-1 transgenic mice 
after pneumococcal infection but not after mock infection (data 
not shown). In keeping with this decreased expression of Mcl-1 
after infection and the rapid turnover of Mcl-1 (6, 7), the decreased 
apoptosis observed in transgenic BMDMs represented a delay in 
apoptosis rather than a sustained inhibition, similar to previous 
observations with Mcl-1 (8, 10). The preservation of Δψm apparent at 
14–18 hours was no longer detectable at 20 hours after infection, and 
the lack of nuclear apoptosis at 20 hours disappeared by 48 hours 
after infection in transgenic BMDMs (data not shown).
Figure 4
Mcl-1 Exon-1 expression is an upstream event in pneumococcal-associated but not UV-associated macrophage apoptosis. (A) Western blot of total pro-
tein from MDMs 20 hours after infection in the presence (+) or absence (–) of zVADfmk (zVAD) or N-benzyloxycarbonyl–Phe-Ala fluoromethyl ketone 
(zFA), probed with anti–Mcl-1, anti–Bcl-xL, and anti-GAPDH antibodies. Data is representative of 4 donors. (B) Western blot of membrane and nuclear 
fractions from MDMs 20 hours after infection, probed with anti–Mcl-1 antibody. Data represent 2 donors and 3 independent experiments. (C) Nuclear 
morphology, detected by DAPI staining, in control MDMs (left panel) or MDMs 12 hours after UV irradiation (right panel). Levels of apoptosis were 1% 
in control MDMs and 34% in UV-irradiated MDMs. (D) Western blot of total protein from MDMs at the indicated time points after UV irradiation, probed 
with anti–Mcl-1, anti-p53, and anti-actin antibodies. The asterisks mark the expected positions of Mcl-1Exon-1. Data are representative of 3 donors.
Figure 5
Proteasome-mediated degradation of Mcl-1 is associated with 
pneumococcal-associated macrophage apoptosis. (A) Western blot of 
total protein obtained from MDMs 12 hours and 20 hours after mock 
infection or infection with pneumococci in the presence or absence of 
the proteasome inhibitor MG-132, probed with anti–Mcl-1 and anti-
actin antibodies. Data are representative of 4 donors in 2 independent 
experiments. (B) Western blot of the cytosolic fractions from MDMs 
20 hours after infection in the presence or absence of MG-132 probed 
with anti–cytochrome c and anti-actin antibodies. Results are repre-
sentative of 3 donors from 2 independent experiments. (C) MDMs 
were incubated in the presence or absence of MG-132, and nuclear 
features of apoptosis were recorded 20 hours after infection. Results 
were obtained from 6 donors tested in duplicate. Dunn’s multiple com-
parison test: MDMs infected with pneumococci without MG-132 vs. 
with MG-132, P < 0.05. Data are representative of 3 experiments.
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Clearance of pneumococci from the lung of Mcl-1 transgenic mice. We have 
previously documented that caspase activation not only contributes 
to apoptosis induction in macrophages following pneumococcal 
phagocytosis (22), but also enhances bacterial clearance (17). In 
association with delayed apoptosis in BMDMs from Mcl-1 trans-
genic mice, we also observed an increased viability of intracellular 
pneumococci (Figure 7A). We have previously described a mouse 
model of pulmonary pneumococcal infection in which apoptosis 
of alveolar macrophages (AMs) contributes to optimal bacterial 
clearance (18). Using this model, we instilled pneumococci into the 
lungs of transgenic or nontransgenic mice and measured apoptosis 
in AMs 14 hours after infection. Transgenic mice had signifi-
cantly fewer apoptotic AMs (Figure 7, B and C) and significantly 
less efficient clearance of bacteria from the lungs (Figure 7D). All 
nontransgenic mice cleared 104 CFU of pneumococci from the 
lung, but at this dose, transgenic mice had detectable numbers of 
bacteria in the lung. In addition, all transgenic mice with more than 
102 CFU in the lung developed bacteremia, a finding not seen in the 
nontransgenic mice. When the inocula of bacteria were increased 
to the threshold at which AM host defenses become overwhelmed, 
nontransgenic mice no longer cleared bacteria completely, but their 
mean bacterial colony count was still lower by a factor of greater 
than 1 on a log scale. For the small number of mice tested (n = 3–4), 
however, this result did not reach statistical significance. Overall, 
these results show that AM apoptosis is decreased in Mcl-1 trans-
genic mice after pneumococcal infection and that this is associated 
with a significant impairment of bacterial clearance.
Discussion
Mcl-1 protein expression regulates macrophage transition from resistance 
to susceptibility to apoptosis during pneumococcal infection. To con-
tribute optimally to host defense, macrophages demonstrate 
biphasic susceptibility to apoptosis. Initial resistance to apoptosis 
in the face of proapoptotic host and microbial factors allows the 
macrophages to contribute to innate immunity (3, 23), but sub-
sequent induction of apoptosis facilitates bacterial clearance and 
minimizes inflammation (18). The molecular events associated 
with this transition are unknown, and the present research has 
stemmed from our interest in identifying factors that regulate 
this switch in macrophage phenotype.
We focused on the model of host-mediated macrophage apoptosis 
during pneumococcal infection, because it is characterized by initial 
Figure 6
Macrophages from Mcl-1 transgenic mice have delayed apoptosis. (A) Western blot of total protein extracted from BMDMs from nontransgenic 
mice (Non-Tg) and mice transgenic for human Mcl-1 (Tg) and probed with anti–human Mcl-1 and anti-actin antibodies. (B) BMDMs from 
nontransgenic and transgenic mice were stained with JC-1 14 hours after mock infection or infection with pneumococci. Data are representa-
tive of 3 experiments. (C) Histograms representing Δψm of BMDMs from nontransgenic and transgenic controls 14 hours after infection, stained 
with JC-1. Results are representative of 3 independent experiments. (D) Nuclear morphology, detected by DAPI staining, in BMDMs from 
nontransgenic and transgenic mice 20 hours after infection. (E) Nuclear features of apoptosis were recorded from BMDMs from transgenic or 
nontransgenic controls 20 hours after infection. P < 0.05, BMDMs infected with pneumococci from transgenic vs. nontransgenic, Dunn’s multiple 
comparison test. Results represent 3 experiments. (F) Western blot of total protein from BMDMs from nontransgenic and transgenic mice 20 
hours after infection, probed with anti–human Mcl-1 and anti-actin antibodies.
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macrophage viability and subsequent macrophage apoptosis 
(17, 18). A tightly regulated biphasic pattern in macrophage sus-
ceptibility to apoptosis is essential for optimal killing of bacteria 
in this model. Pneumococci are innately resistant to phagocytosis 
and challenge the capacity of host defenses to clear bacteria suc-
cessfully (24). Nevertheless, phagocytosis of opsonized bacteria by 
macrophages results in clearance of bacteria without intracellular 
persistence and is associated with macrophage apoptosis (22, 24). 
In contrast to mycobacteria, which tend to persist intracellularly 
(25, 26), the pneumococcal model of host-mediated macrophage 
apoptosis involves phagocytosis and acute bacterial killing with-
out prolonged intracellular survival (22), enabling investigation of 
biphasic susceptibility to apoptosis.
Mcl-1 has been identified as a specific determinant of the resis-
tance of macrophages to apoptosis and acts during periods of 
changing cell phenotype (2, 5). As shown in this work, upregulation 
of Mcl-1 mRNA was associated with sustained macrophage viabil-
ity for at least 14 hours after exposure to pneumococci. As proof of 
concept, transfection of U937 cells with Mcl-1 decreased the level 
of apoptosis after pneumococcal infection. Furthermore, trans-
genic mice overexpressing Mcl-1 exhibited reduced apoptosis after 
pneumococcal infection, both in BMDMs in vitro and in AMs in vivo. 
Mcl-1 upregulation in macrophages is a feature of mycobacterial 
infection (16), and enhanced Mcl-1 gene transcription has been iden-
tified in brain endothelium during infection with the group B strep-
tococcus, an organism closely related to the pneumococcus (27). It is 
plausible that Mcl-1 upregulation may be utilized by a broad range 
of cell types to prevent apoptosis during infection (28).
Bcl-2 family proteins protect against apoptosis during conditions 
of increased cell stress, including nitrosative or oxidative stress 
(29, 30), which prevail in macrophages loaded with bacteria (31). 
Mice deficient in adenine nucleotide translocator 1 demonstrate 
oxidative stress and upregulate Mcl-1 (32). In the first 12–14 hours 
after phagocytosis of pneumococci, Mcl-1 aids maintenance of 
mitochondrial homeostasis despite increasing cell stress. Follow-
ing this period of macrophage viability, Mcl-1 expression declines, 
and signs of MMP and apoptosis are observed. Even BMDMs 
from Mcl-1 transgenic mice exhibited only a delay in MMP. Mcl-1 
downregulation is a feature of cell stress pathways (13), and a DNA 
damage–response pathway that mediates apoptosis in association 
with Mcl-1 downregulation with enhanced Bak-Bax heterodimer-
ization has recently been described in HeLa cells infected with 
adenovirus and contributes to antiviral host defense (12). Late 
decreases in Mcl-1 protein levels were the result of both transla-
tional downregulation, and active proteasomal degradation–cel-
lular stress pathways may influence both these processes (12, 13). 
Increased protein degradation was a constant finding, whereas the 
timing of downregulation of mRNA was variable with some donors 
showing decreased mRNA only after 20 hours. The critical deter-
minant of the onset of apoptosis induction in this model seemed 
to be the timing of initial decline of Mcl-1 expression from peak 
levels rather than the time at which the absolute level of Mcl-1 fell 
below the level expressed in mock-infected cells. Nitrosative/oxida-
tive stress can trigger apoptosis in DNA-damage pathways (33), and 
we have recently shown that NO production contributes to MMP in 
pneumococcal-associated macrophage apoptosis (34). Mcl-1 may be 
downregulated in response to cellular stresses such as nitrosative/
oxidative stress, nucleotide depletion, or accumulating DNA dam-
age in macrophages loaded with pneumococci. It has been reported 
that accumulating nitrosative stress in cells initially does not induce 
apoptosis, as glycolytic ATP production maintains viability, but once 
this source of ATP production fails, oxidative stress supervenes and 
MMP results (35). Therefore the initial mitochondrial protection 
provided by Mcl-1 is likely to be overwhelmed by the combination 
of Mcl-1 downregulation and accumulating cell stress.
Generation of a novel BH3-only isoform of Mcl-1 is associated with 
macrophage apoptosis during pneumococcal infection. We documented 
upregulation of a novel isoform of Mcl-1 of approximately 34 
kDa that is compatible with Mcl-1Exon-1, a BH3-only protein, after 
pneumococcal infection (but not after UV-induced apoptosis). 
Expression of this protein required active transcription but was 
not blocked by inhibitors of caspases, cathepsins, calpains, or serine 
proteases. Transfection of Mcl-1Exon-1 into U937 cells confirmed that 
this protein was proapoptotic and had effects comparable to those 
of Bax in enhancing apoptosis in both the absence or the presence 
of pneumococcal infection. Alternative splicing is a feature of many 
Bcl-2 proteins, and generation of an isoform in association with 
retention of an intron and generation of an open reading frame 
arising from a continuous genomic sequence has been described 
for the Bcl-x isoform Bcl-xβ (36). Although no specific binding part-
ners of Mcl-1Exon-1 have been identified, it is interesting to note that 
another isoform of Mcl-1, Mcl-1S/ΔTM (14), binds (and potentially 
neutralizes) full-length Mcl-1 (15). In addition, the localization of 
Figure 7
Mcl-1 transgenic mice demonstrate decreased AM apoptosis and 
decreased bacterial clearance from the lung. (A) Intracellular killing assays 
were performed in BMDMs from Mcl-1 transgenic and nontransgenic 
controls 14 hours after infection. Results are representative of 4 separate 
experiments. P < 0.05, transgenic vs. nontransgenic; Wilcoxon signed 
rank test. Transgenic and nontransgenic mice received an intratracheal 
instillation of the indicated dose of pneumococci. (B and C) Percent-
age apoptotic macrophages in bronchial alveolar fluid from transgenic 
vs. nontransgenic mice after instillation of 104 CFU pneumococci as 
assessed by (B) Annexin V/ToPro 3 staining and flow cytometry (P < 0.01; 
n = 6–8) and (C) nuclear morphology on cytospins (P < 0.01; n = 6–8). (D) 
Bacterial CFU in lungs of transgenic vs. nontransgenic mice (104 CFU, 
P < 0.05, n = 6–8; 105 CFU, P > 0.05, n = 3–4).
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Mcl-1Exon-1 (which lacks the C-terminal transmembrane domain) to 
the mitochondrial fraction, suggests that it may interact with Bcl-2 
family members already anchored to the mitochondrial membrane. 
Activated BH3-only proteins can bind antiapoptotic Bcl-2 proteins 
releasing Bak/Bax from inhibition or directly activating Bak-Bax 
for MMP induction (37, 38).
Many Bcl-2 family isoforms have been identified and have been 
best characterized in BH3-only proteins such as Bim (39). Howev-
er, these isoforms have been described in transformed cell lines or 
experiments involving cloning systems (40). There has been little 
information on the expression of Bcl-2 family isoforms during phys-
iologic events such as infection or inflammation. The only reports 
concern the induction of 3 murine A1 isoforms in mice exposed 
to bacillus Calmette-Guerin, although these isoforms arise from 
transcription of 3 separate genes and do not arise from differen-
tial splicing (41). In contrast, in the present system, the differential 
splicing of a single gene would result in expression of an isoform 
that opposes the function of the full-length protein. Importantly, 
this isoform is not expressed by mock-infected macrophages, and 
its putative expression in infected cells occurs before Mcl-1 tran-
scription starts to fail, suggesting that the splicing event is not the 
result of failure of gene transcription. The opposing functions of 
full-length Mcl-1 and Mcl-1Exon-1 were confirmed by transfection of 
U937 cells, illustrating that differential splicing of the Mcl-1 gene is 
a key event in regulating susceptibility of macrophages to apoptosis 
during infection. Thus, bacterial infection is a stimulus for alterna-
tive splicing of Bcl-2 family genes.
The importance of tightly regulating the onset of apoptosis induction in 
macrophage-mediated antibacterial defense. The dynamic regulation 
of Mcl-1 isoform expression apparently determines the timing of 
MMP and the switch in macrophage susceptibility to apoptosis 
during pneumococcal infection. The importance of this path-
way to the host is illustrated by the variety of strategies employed 
by bacteria to subvert this process, for instance, by initiating 
apoptosis downstream of MMP (42). Bacteria may induce macro-
phage apoptosis in the first few hours after exposure, killing the 
macrophages before key host defense functions are completed 
(43). Although these forms of pathogen-mediated apoptosis most 
often involve direct caspase activation, induction of Mcl-1 deg-
radation by Shiga toxin has been described in endothelial cells 
(44). In contrast, M. tuberculosis delays host-mediated macrophage 
apoptosis to prolong intracellular survival (45). Although a variety 
of mechanisms, including modulation of death receptor signaling, 
have been implicated in this process (45), evidence of upregulation 
of antiapoptotic Bcl-2 proteins, including Mcl-1 and A1, has been 
reported (16, 41). Inhibition of MMP in macrophages during bac-
terial infection has also been identified as a mechanism by which 
intracellular bacteria ensure prolonged survival (42).
Mcl-1 probably also contributes to the regulation of apoptosis 
in neutrophils during infection, as it has been shown to medi-
ate apoptosis inhibition by GM-CSF, IL-1β, or bacterial 
lipopolysaccharide (46). Furthermore, proteasome inhibition 
delays neutrophil apoptosis in association with decreased turn-
over of Mcl-1 (47). Upregulation of Mcl-1 can delay apoptosis in 
neutrophils during Toxoplasma gondii infection, demonstrating 
its role in prolonging survival of phagocytes engaged in criti-
cal host defense functions (48). In view of the important role of 
neutrophils in successful resolution of pneumococcal pneumonia 
(49), it is likely that levels of Mcl-1 expression in neutrophils also 
contribute to the outcome of pneumococcal infection.
Although altered Mcl-1 expression in cells during exposure to 
microorganisms has been described previously (16, 27, 44, 48), the 
functional consequences of altered Mcl-1 expression in vivo during 
the host response to infection have not previously been demon-
strated. We demonstrate that delaying the induction of apoptosis by 
overexpressing Mcl-1 in macrophages from Mcl-1 transgenic mice 
reduces AM apoptosis as well as the efficiency of bacterial clear-
ance in a subclinical model of pneumococcal infection. Because this 
model is not associated with significant recruitment of neutrophils 
and AMs are the major source of apoptotic cells in this model (18), 
it is likely that AMs — and by extension, AM apoptosis — indeed play 
a critical role in antibacterial host defense. Thus, inhibition of AM 
apoptosis by 2 different experimental systems, namely overexpression 
of Mcl-1 (this study) and caspase inhibition (18), is associated with 
an increased likelihood of bacteremia, suggesting that AM apoptosis 
has an important role in preventing invasive pneumococcal disease.
Factors activated during apoptosis induction could also contrib-
ute to antibacterial host defense by directly killing bacteria. Caspase 
activation occurs downstream of Mcl-1 downregulation and MMP 
in macrophages following pneumococcal infection. The identity of 
the caspases involved requires delineation, but experiments with 
caspase-1–deficient mice suggest that caspase-1 does not play a 
role (H.M. Marriott and D.H. Dockrell, unpublished data). Loss of 
MMP has been associated with increased ROS and NO production, 
which could contribute to bacterial killing and/or provide an addi-
tional stimulus for caspase activation (50). These considerations 
are important in optimizing the use of experimental therapies 
such as NO synthase and caspase inhibitors (51, 52). Although they 
may improve survival in models of overwhelming infection, they 
could worsen the outcome in subclinical infection by delaying the 
apoptosis phase necessary for optimal bacterial killing (18).
Conclusion. We provide evidence that pneumococcal-associated 
macrophage apoptosis represents a host defense that is tightly 
regulated by the dynamic alteration and pattern of Mcl-1 isoform 
expression. Upregulation of full-length Mcl-1 initially main-
tains macrophage viability, while subsequent downregulation of 
full-length Mcl-1 and upregulation of a proapoptotic isoform, 
Mcl-1Exon1, triggers MMP. Transgene-enforced overexpression of 
Mcl-1 delays the onset of apoptosis induction and impedes mac-
rophage-mediated bacterial clearance.
Methods
Bacteria. Type 1 S. pneumoniae (WHO reference laboratory strain, SSISP; Stat-
ens Seruminstitut) were grown as previously described and opsonized in 
RPMI (Sigma-Aldrich) containing 10% anti-pneumococcal immune serum 
(22). In experiments involving murine cells, bacteria were opsonized in serum 
from immunized mice with detectable antibodies against type 1 S. pneumoniae 
(53). For in vivo infection, type 2 S. pneumoniae (D39 strain) were used (18).
Cells and infection. Human PBMCs were isolated from whole blood donat-
ed by healthy volunteers as previously described with informed consent 
as approved by the South Sheffield Regional Ethics Committee of Royal 
Hallamshire Hospital (Sheffield, United Kingdom) (22). Murine BMDMs 
were obtained by culturing marrow from mice expressing human Mcl-1 
as a transgene or from nontransgenic littermates (10). Marrow cells were 
plated at 0.5 × 106 cells/ml and cultured as described in DMEM (Sigma-
Aldrich) containing 10% FCS and 10% L929 conditioned medium (18). At 
14 days, representative wells were scraped to determine the concentration 
of BMDMs. U937 cells were cultured in RPMI plus 10% FCS, 2 mM Gluta-
MAX (Invitrogen Corp.), 10 mM HEPES (Invitrogen Corp.), 1 mM sodium 
pyruvate (Invitrogen Corp.) and 4.5 g/l of glucose (Sigma-Aldrich). MDM 
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or BMDM cultured for 14 days or U937 cells were infected with opsonized 
S. pneumoniae at a MOI of 10 or mock-infected (22). In certain experiments, 
10 μM MG-132 (Calbiochem) as a proteasome inhibitor; 50 μM zVADfmk 
(Enzymes Systems Products) as a pan-caspase inhibitor; N-benzyloxycar-
bonyl–Phe-Ala fluoromethyl ketone (Enzyme Systems Products) as a con-
trol for zVADfmk; 50 μM ALLN (Calbiochem) as a calpain I and II inhibitor; 
50 μM Cathepsin Inhibitor I (Calbiochem) as a cathepsin B, L, and S, and 
papain inhibitor; or complete protease inhibitor cocktail (Roche) as a broad 
spectrum serine and cysteine protease inhibitor was added 1 hour before 
infection and after washing at 4 hours. Actinomycin D (5 μg/ml; Sigma-
Aldrich) was added 4 hours after infection. For UV irradiation, MDMs were 
exposed to 120 mJ/cm2 of irradiation (Stratalinker 1800; Stratagene).
Generation of MCL-1 expression constructs. Expression constructs contain-
ing Mcl-1WT and Mcl-1S/ΔTM sequences, pcDNA Bax, and insertless pCR3.1 
vector were as described (14). For generation of the pCR3.1 Mcl-1Exon1 con-
struct, the following primer pairs were used: Mcl-1 Kozak F 5′-GCCAC-
CATGTTTGGCCTCAAAAGAAACGCG-3′, Mcl-1 EX1R 5′-GAATTCT-
TAATGAACCCGCTTACCTTG-3′, with genomic DNA as template. The 
resulting fragments were excised from agarose gels, and the DNA was 
extracted using the QIAEXII Gel Extraction Kit (Qiagen) and directly 
cloned into pCR3.1 TOPO (Invitrogen Corp.).
SDS-PAGE and Western immunoblotting. Whole-cell extracts and cytosolic 
and membrane fractions were extracted as described (34). For detection 
of AIF in nuclear fractions, cells were lysed in buffer containing 20 mM 
HEPES, 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, 1 mM 
DTT, 250 mM sucrose, and protease inhibitor cocktail as described (54). 
The pellet was resuspended in lysis buffer (nuclear fraction). The super-
natant was spun at 10,000 g for 15 minutes at 4°C. The pellet was resus-
pended in lysis buffer (mitochondrial fraction); the supernatant was 
spun at 500,000 g for 1 hour at 4°C, and the resulting supernatant was 
used as the cytosolic fraction. Protein was quantified using a modified 
Lowry protocol (DC protein assay; Bio-Rad Laboratories), and equal pro-
tein was loaded per lane, either 25 μg of total protein or 10 μg of protein 
from cell fractions. Samples were separated by SDS-PAGE (12% or 15%) 
and blotted onto nitrocellulose membranes (Bio-Rad Laboratories) with 
protein transfer confirmed by Ponceau S staining. Blots were incubated 
overnight at 4°C with antibodies against Mcl-1 (rabbit polyclonal SC-19, 
1:500; Santa Cruz Biotechnology Inc. or rabbit polyclonal, 1:1,000; BD 
Biosciences), cytochrome c (mouse monoclonal, clone 7H8.2C12, 1:1,000; 
BD Biosciences), Bcl-xL (rabbit polyclonal, 1:1,000; BD Biosciences), p53 
(mouse monoclonal, clone DO-1; Santa Cruz Biotechnology Inc.), actin 
(goat polyclonal, 1:500; Santa Cruz Biotechnology Inc. or rabbit polyclonal, 
1:2,000; Sigma-Aldrich), GAPDH (mouse monoclonal, 1:2,000; Chemicon), 
Histone H1 (AE-4, mouse monoclonal, 1:500; Santa Cruz Biotechnology 
Inc.) or AIF (1:1,000) (19). Protein detection was done with HRP-conjugat-
ed secondary antibodies (Dako) and ECL (Amersham Pharmacia). Bands 
were quantified using Image J 1.32 software (NIH), and after confirming 
equivalence of Ponceau S staining for each time point, Mcl-1 bands were 
compared with the mean of the mock-infected bands for that donor.
In vitro translation. To prepare Mcl-1 proteins, a coupled in vitro tran-
scription/translation system (Promega) was used in accordance with the 
manufacturer’s instructions using Mcl-1 constructs in pCR3.1.
RNase protection assay. Total RNA was harvested from MDMs cul-
tured in 25-cm2 plastic flasks using guanidine isothiocyanate solution 
(4 M guanidine isothiocyanate, 5 mM sodium citrate [pH 7.0], 0.1 M 
β-mercaptoethanol [all Sigma-Aldrich]) and CsCl as previously described (55). 
Assays were performed using 5 mg of RNA and the APO-2b probe set 
according to the RiboQuant protocol (BD Biosciences).
Apoptosis detection. Nuclear morphology was examined on all cells by DAPI 
(Molecular Probes) as previously reported (22). Apoptosis was estimated by 
blinded reviewers who counted 300 cells per coverslip in duplicate samples 
for the presence of condensed or fragmented nuclei. To detect loss of Δψm, 
cells were stained in 250 μL RPMI containing 10 μM 5,5′,6,6′-tetrachloro-
1,1′,3,3′-tetraethylbenzimidazolocarbocyanine iodide (JC-1) (Molecular 
probes) and 2 μM Hoechst 33342 (Calbiochem) as a nuclear counterstain 
for 30 minutes at 37°C. Coverslips were mounted and examined by fluo-
rescent microscopy. Loss of Δψm was confirmed by loss of red punctate 
staining. In these experiments, MDMs pretreated with 5 μM staurosporine 
(Sigma-Aldrich) for 2 hours were used as a positive control. To quantify loss 
of Δψm, 2 × 106 cells were stained with JC-1 as above, washed, scraped, and 
analyzed by a FACSCalibur flow cytometer (BD Biosciences — Pharmingen). 
At least 10,000 cells were analyzed for each experimental condition.
Transient transfection with Mcl-1 isoform constructs to assess effects on cell death. 
pCR3.1-based vectors (0.5 μg) were transiently transfected into U937 cells 
together with pcDNA Bax as a positive control, and empty pCR3.1 vector 
as a negative control; 0.5 μg of vector expressing EGFP was cotransfected 
as a reporter. Transfection was by nucleofection (Amaxa GmbH), in 
accordance with the manufacturer’s protocol, 4 hours after infection. 
Cytospin preparations were performed 16 hours after transfection, and 
apoptosis was assessed as above.
Bacterial killing assay. The intracellular bacterial killing assay was per-
formed at 14 hours as previously described (34) with quadruplicate wells 
lysed for each data point.
In vivo infection. Mcl-1 transgenic mice or nontransgenic littermates were 
infected by intratracheal instillation of 104 or 105 CFU type 2 S. pneumoniae, 
as described previously (18). Mice were killed 14 hours after infection, 
and bronchoalveolar lavage and lungs were collected. Bacterial numbers 
in blood and lung and AM apoptosis, assessed by flow cytometry after 
Annexin V-PE/ToPro 3 staining, or assessment of nuclear morphology 
on cytospin preparations were as previously described (18). All animal 
experiments were conducted in accordance with the Home Office Animals 
(Scientific Procedures) Act of 1986 and was approved by the animal project 
review committee of the University of Sheffield.
Statistics. Results are recorded as mean and SEM. Parametric or 
nonparametric testing was performed with the indicated tests using Prism 
4.0 software (GraphPad Inc.). Significance was defined as P < 0.05.
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